What are the clinical indications for faropenem?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Indications for Faropenem

Faropenem is indicated for community-acquired bacterial infections including urinary tract infections (UTIs), upper respiratory tract infections (acute bacterial sinusitis, acute exacerbations of chronic bronchitis), community-acquired pneumonia, uncomplicated skin and soft tissue infections, and pediatric infections—though it is currently approved only in Japan and India, not by the FDA. 1, 2, 3

Primary Indications

Urinary Tract Infections

  • Acute uncomplicated cystitis in adult women, particularly when caused by ESBL-producing Escherichia coli and Klebsiella pneumoniae 4, 5
  • Faropenem demonstrates activity against third-generation cephalosporin-resistant E. coli and K. pneumoniae, including ESBL producers 5
  • Recommended dosing: 7-day regimen shows superior microbiological eradication compared to 3-day treatment (66.7% vs 58.9%, P=0.048), though clinical efficacy is similar 4
  • Important caveat: UTI persistence or recurrence occurs in 16% at 28 days and 25% at 90 days, even with appropriate treatment 5

Respiratory Tract Infections

  • Acute bacterial sinusitis: 7-day or 10-day regimens (300 mg twice daily) show clinical cure rates of 80.3% and 81.8%, respectively, comparable to cefuroxime axetil 6
  • Acute exacerbations of chronic bronchitis 3
  • Community-acquired pneumonia 3

Skin and Soft Tissue Infections

  • Uncomplicated skin and skin structure infections with efficacy equivalent to comparators like amoxicillin-clavulanate 3

Pediatric Infections

  • Approved in some regions for upper respiratory tract infections, UTIs, dermatological infections, and bacterial periodontal infections in children 2
  • Pediatric dosing: 15 mg/kg/day divided into three doses, available as oral dry syrup 2

Key Microbiological Activity

Faropenem has broad-spectrum activity against:

  • Gram-positive and Gram-negative aerobes and anaerobes 3
  • ESBL-producing Enterobacterales 7, 5
  • AmpC β-lactamase-producing organisms 5
  • Fluoroquinolone-resistant and cephalosporin-resistant E. coli strains 4

Critical limitations—NOT active against:

  • Methicillin-resistant Staphylococcus aureus (MRSA) 3
  • Vancomycin-resistant Enterococcus faecium 3
  • Pseudomonas aeruginosa 3
  • Stenotrophomonas maltophilia 3

Important Clinical Considerations

Regulatory Status

The FDA rejected faropenem approval for all four indications (acute bacterial sinusitis, acute exacerbations of chronic bronchitis, community-acquired pneumonia, and uncomplicated skin infections), citing inadequate placebo-controlled trials and concerns about study validity 3. This limits its use to countries where it has received approval (Japan and India).

Resistance Concerns

  • Limited evidence suggests potential for resistance development after faropenem treatment 7
  • Preliminary data indicate possible cross-resistance to carbapenems, which is concerning given carbapenems' role as last-resort antibiotics 7
  • Dedicated surveillance monitoring is needed to understand resistance patterns 7

Dosing Variability

Faropenem dosing regimens vary broadly within and between indications, reflecting limited standardization 7. The most common adult regimen is 300 mg twice daily for 7-10 days 6.

Safety Profile

Faropenem demonstrates a favorable safety profile with adverse events reported in approximately 9.5% of patients, most commonly diarrhea 4, 3. Discontinuation rates are similar to comparator antibiotics 6.

Clinical Decision Algorithm

For UTIs caused by ESBL-producing Enterobacterales:

  • Consider faropenem when disk diffusion zone diameter >16 mm (estimated MIC ≤2.2 mg/L) 5
  • Use 7-day regimen for optimal microbiological eradication 4
  • Monitor for recurrence at 28 and 90 days 5

For respiratory tract infections:

  • 7-day regimen is adequate for acute bacterial sinusitis 6
  • Reserve for patients with β-lactamase-producing organisms when other options are limited 3

Avoid faropenem when:

  • MRSA, P. aeruginosa, or VRE are suspected 3
  • In regions where it lacks regulatory approval (including the United States) 3
  • Carbapenem-sparing strategies are prioritized due to cross-resistance concerns 7

References

3
Research

Faropenem: review of a new oral penem.

Expert review of anti-infective therapy, 2007

6
Research

Randomized double-blind study comparing 7- and 10-day regimens of faropenem medoxomil with a 10-day cefuroxime axetil regimen for treatment of acute bacterial sinusitis.

Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2006

Related Questions

What is the appropriate treatment and dosage of Faropenem (a broad-spectrum antibiotic) for a patient with a suspected bacterial infection, considering potential antibiotic resistance and impaired renal function?
Can faropenem 300 mg twice daily (BID) be given?
Can faropenem (oral carbapenem) be used as step‑down therapy from meropenem (intravenous carbapenem)?
What are the indications for feropenam 200 mg tablets?
What is the efficacy of faropenem, and can it be used as an oral equivalent of parenteral carbapenems?
In a 63-year-old male former smoker with a one‑day history of nonproductive cough who is afebrile and has no dyspnea or systemic symptoms, what is the most appropriate initial management?
What is the recommended NutriBest feeding regimen for a 73‑kg patient whose primary source of nutrition is NutriBest?
How is a large hiatal hernia that is mostly intrathoracic repaired, and why is a fundoplication performed with the repair?
For a 73‑kg patient receiving NutriBest powder as the primary nutrition, how many scoops should be administered daily to achieve the target caloric (~2000 kcal) and protein (90–110 g) intake?
What is the likely diagnosis and appropriate management for a patient with low red blood cell count, ferritin 23 ng/mL, serum iron 80 µg/dL, transferrin 308 mg/dL, total iron‑binding capacity 385 µg/dL, and iron saturation 21%?
Patient scheduled for lumbar fusion in three weeks with iron‑deficiency anemia (ferritin 23 ng/mL); is intravenous iron infusion appropriate?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.